2018 American Transplant Congress
Predictive Value of mRECIST in HCC Response to the Neoadjuvant Locoregional Therapies and Prognosis Affected by the Peak AFP Level before Liver Transplantation
PURPOSE: The modified response evaluation criteria in solid tumors (mRECIST) has been used to assess the response of hepatocellular carcinoma (HCC) to locoregional therapy (LRT)…2018 American Transplant Congress
HLA-DR4 Matching and Hepatocellular Carcinoma Recurrence after Liver Transplantation
PURPOSE: The phenomenon of graft versus host disease after orthotopic liver transplantation (OLT) is estimated at approximately 1-2%, suggesting that under some circumstances, the graft…2018 American Transplant Congress
Vascular Invasion and Survival after Liver Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry
PurposeStudies suggest that vascular invasion may be a superior prognostic marker compared with traditional selection criteria, e.g. Milan criteria. We aimed to investigate the prognostic…2018 American Transplant Congress
Post-Transplant Outcomes under the New HCC Exception Policy
Surgery, Johns Hopkins Medical Institute, Baltimore, MD.
In October 2015, OPTN implemented a new policy for liver allocation, under which hepatocellular carcinoma (HCC) patients receive exception points only after a 6-month delay.…2018 American Transplant Congress
Locoregional Treatments before Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study from the European Liver Transplant Registry
PurposeLocoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has shown to improve survival. However, effect of treatment types…2018 American Transplant Congress
Financial Burden of Liver Transplant vs Resection for HCC
Surgery, Indiana University, Indianapolis, IN.
There is considerable commentary regarding liver transplant vs resection for the treatment of hepatocellular carcinoma (HCC). While liver transplant provides longer survival when compared to…2018 American Transplant Congress
A Long-Term Experience with Expansion of Milan Criteria for Liver Transplant Recipients
1Duke University, Durham, NC; 2Baylor College of Medicine, Houston, TX.
Background: The Milan Criteria (MC) have historically determined eligibility for transplantation for hepatocellular carcinoma (HCC). The United Network for Organ Sharing (UNOS) Region 4 expanded…2018 American Transplant Congress
Intention to Treat Outcomes of Patients with Hepatocellular Carcinoma Downstaged to within Milan
Objectives: The success of LRT has served as a tool to select a subgroup of patients exceeding transplant criteria but potentially achieving meaningful outcome with…2018 American Transplant Congress
Validation of the alpha-Fetoprotein Model for Hepatocellular Carcinoma Recurrence after Transplantation in an Asian Population
Department of Surgery, Samsung Medical Center, Seoul, Republic of Korea.
Background: This study was designed to validate the alpha-fetoprotein model for predicting recurrence after LT in Korean HCC patients.Methods: Patients who underwent liver transplantation for…2018 American Transplant Congress
Cost Analysis of Loco-Regional Bridging Therapy for Hepatocellular Carcinoma: A National Study
Liver transplantation (LT) is cost-effective in the primary treatment of Hepatocellular carcinoma (HCC). Loco-regional therapies (LRTs) have increased as both primary therapy for HCC as…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 23
- Next Page »